Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of NaliCap (nal-IRI + capecitabine) versus NAPOLI (nal-IRI + 5-FU + leucovorin) in gemcitabine-pretreated advanced pancreatic cancer
KCT0004845Phase 2Not yet recruiting
- Sponsor
- Servier
- Start
- May 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of nanoliposomal irinotecan, capecitabine, fluorouracil and folinic acid in pancreatic cancer (PC) (2 arms), sponsored by Servier. Planned start May 2020; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecancapecitabinefluorouracilfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0004845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004845.